Setting new standards in information exchange for the pharmaceutical and biotech industry
EU Commission Approves the First and Only Immuno-Oncology Combination for Treatment of Advanced Melanoma
May 16, 2016
Earlier this year, the FDA approved the combination of BMS’ ipilimumab (Yervoy) plus nivolumab (Opdivo) for metastatic melanoma and Europe soon followed with last weeks approval by the European Commission, making this combination Europe’s first and only approved combination of 2 immuno-oncology agents.
We were delighted to have Dr Jedd Wolchok of Memorial Sloan Kettering Cancer Center present the most recent data regarding the Immuno-Immuno Combinations of Yervoy + Opdivo in Melanoma at the IO360° conference that took place in February in NYC. (For a copy of the slides from his session, see below)
We look forward to addressing more on this topic at the Rational Combinations 360° conference, June 23-24 2016, NYC.
To read the full article, click here.
To access Dr Wolchok’s presentation from IO360°, click here.
For more information about Rational Combinations 360° conference, see link below and utilize code BLOG10 for 10% off the registration, click here.